Evidence map›Paper›PMID 27353001›Full record

ArticleInternational journal of molecular medicine2016

Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.

Sinéad T Aherne, Paul Smyth, Michael Freeley, Leila Smith, Cathy Spillane, John O'Leary, Orla Sheils

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sinéad T AherneNational Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Republic of Ireland.
Paul SmythDepartment of Histopathology, Trinity College Dublin, Dublin 8, Republic of Ireland.
Michael FreeleyDepartment of Clinical Medicine and Trinity Translational Medicine Institute, Trinity College Dublin, Dublin 8, Republic of Ireland.
Leila SmithFluidigm Corporation, Suite 100, South San Francisco, CA 94080, USA.
Cathy SpillaneDepartment of Histopathology, Trinity College Dublin, Dublin 8, Republic of Ireland.
John O'LearyDepartment of Histopathology, Trinity College Dublin, Dublin 8, Republic of Ireland.
Orla SheilsDepartment of Histopathology, Trinity College Dublin, Dublin 8, Republic of Ireland.
Trinity College Dublin · IEDublin City University · IEFluidigm (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer is the most common endocrine malignancy and accounts for the majority of endocrine cancer-related deaths each year. Our group and others have previously demonstrated dysfunctional microRNA (miRNA or miR) expression in the context of thyroid cancer. The objective of the present study was to investigate the impact of synthetic manipulation of expression of miR-25 and miR-222 in benign and malignant thyroid cells. miR-25 and miR-222 expression was upregulated in 8505C (an anaplastic thyroid cell line) and Nthy-ori (a SV40-immortalised thyroid cell line) cells, respectively. A transcriptomics-based approach was utilised to identify targets of the two miRNAs and real-time PCR and western blotting were used to validate a subset of the targets. Almost 100 mRNAs of diverse functions were found to be either directly or indirectly targeted by both miR-222 and miR-25 [fold change ≥2, false discovery rate (FDR) ≤0.05]. Gene ontology analysis showed the miR-25 gene target list to be significantly enriched for genes involved in cell adhesion. Fluidigm real-time PCR technologies were used to validate the downregulation of 23 and 22 genes in response to miR-25 and miR-222 overexpression, respectively. The reduction of the expression of two miR-25 protein targets, TNF-related apoptosis‑inducing ligand (TRAIL) and mitogen-activated protein kinase kinase 4 (MEK4), was also validated. Manipulating the expression of both miR-222 and miR-25 influenced diverse gene expression changes in thyroid cells. Increased expression of miR-25 reduced MEK4 and TRAIL protein expression, and cell adhesion and apoptosis are important aspects of miR-25 functioning in thyroid cells.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCell Transformation, NeoplasticDown-RegulationHumansMAP Kinase Kinase 4MicroRNAsThyroid Carcinoma, AnaplasticThyroid NeoplasmsTNF-Related Apoptosis-Inducing LigandMAP2K4 protein, humanMAP Kinase Kinase 4MicroRNAsMIR222, humanMIRN25 microRNA, humanTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID27353001
PMCPMC4935456
OpenAlexW2474265105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.